Shots:
- J&J has entered into a definitive agreement to acquire Halda Therapeutics, strengthening its oncology pipeline
- As per the deal, J&J will acquire Halda for $3.05B in cash, with the deal treated as a business combination & expected to close in the coming months
- Acquisition will add Halda’s Regulated Induced Proximity TArgeting Chimera (RIPTAC) platform to advance oral targeted therapies for solid tumors & beyond, plus various other candidates for breast, lung & other cancers, incl. lead asset HLD-0915 (currently in P-I/II) for prostate cancer
Ref: J&J| Image: Halda Therapeutics | Press Release
Related News:- VantAI Collaborates with Halda Therapeutics to Discover RIPTAC Medicines
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
